ABSTRACT Background: In men, the prostatic carcinoma (Pca) is the second most prevalent cancer, and according to Globicon 2022, it is the 5 th predominant cause of cancer death. The prostate-specific antigen (PSA) lacks high specificity and sensitivity rate, which is typically involving over diagnosis, unnecessary biopsy and lacks tumour specificity.Hence, other novel biomarkers which are having high specificity and sensitivity rate along with can be available at patient convenience and affordable prices. Aims: (1) To determine the association of mean platelet volume (MPV) and platelet distribution width (PDW) in prostate carcinoma and benign prostate hyperplasia and (2) To evaluate the association of clinicopathological parameters of Pca with MPV, PDW and PSA. Materials and Methods: This study included 110 PCa patients and 129 benign prostatic hyperplasia (BPH) patients, which included all clinical and laboratory details of the patient, and the obtained data were analysed for the ability of MPV and PDW alone or in combination with PSA to differentiate between BPH and PCa. To evaluate this area under the ROC curve (AUC) obtained by receiver operating curve was used. Results: Compared to BPH patients, PCa patients had higher PSA and PDW levels and lower MPV. AUC values for individual biomarkers ranged from 0.941 for PSA to 0.954 for PDW. The AUC was considerably higher when PSA, MPV and PDW were combined than when they were used alone, rising to 0.965 (0.891–0.970). Conclusions: The combined assessment of PSA with platelet indices such as MPV and PDW offers a novel, inexpensive and easily implementable strategy distinguish BPH from Pca. This triad helps in guiding timely interventions and optimising the patient outcomes.
Hadimani et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: